Abstract:Background Vascular calcification (VC), associated with enhanced cardiovascular morbidity and mortality, is characterized by the osteogenic transdifferentiation of vascular smooth muscle cells. Inflammation promotes VC initiation and progression. Interleukin (IL)‐29, a newly discovered member of type III interferon, has recently been implicated in the pathogenesis of autoimmune diseases. Here we evaluated the role of IL‐29 in the VC process and underlying inflammatory mechanisms. Methods and Results The mRNA expression of IL‐29 was significantly increased and positively associated with an increase in BMP2 (bone morphogenetic protein 2) mRNA level in calcified carotid arteries from patients with coronary artery disease or chronic kidney disease. IL‐29 and BMP2 proteins are colocalized in human calcified arteries. IL‐29 binding to its specific receptor IL‐28Rα (IL‐28 receptor α) (IL‐29/IL‐28Rα) inhibited the proliferation of rat vascular smooth muscle cells without altering cell apoptosis or migration. IL‐29 promoted the calcification of rat vascular smooth muscle cells and their osteogenic transdifferentiation in vitro as well as the rat aortic ring calcification ex vivo, induced by the calcification medium or osteogenic medium. The procalcification effect of IL‐29 was reduced by pharmacological inhibition of IL‐29/IL‐28Rα binding as well as suppression of janus kinase 2/signal transducer and activator of transcription pathway activation, accompanied by decreased BMP2 expression in the cultured rat vascular smooth muscle cells. Conclusions These results suggest an important role of IL‐29 in VC development, at least partly, via activating the janus kinase 2/signal transducer and activator of transcription 3 signaling. Inhibition of IL‐29 or its specific receptor, IL‐28Rα, may provide a novel strategy to reduce VC in patients with vascular diseases. Nonstandard Abbreviations and Acronyms ARS alizarin red S BMP2 bone morphogenetic protein 2 VC vascular calcification VSMC vascular smooth muscle cell Clinical Perspective What Is New? Interleukin (IL)‐29 expression is increased in calcified carotid arteries from patients with coronary artery disease or chronic kidney disease, positively associated with BMP2 (bone morphogenetic protein 2) mRNA, and colocalizes with BMP2 protein. IL‐29, as a proinflammatory cytokine, binds to its specific receptor, IL‐28Rα (interleukin receptor α), on vascular smooth muscle cells, at least partly activating janus kinase 2/signal transducer and activator of transcription 3 signaling pathway to upregulate BMP2 expression in vascular smooth muscle cells, and promotes their osteogenic transformation and calcification. What Are the Clinical Implications? Our results indicate that inhibition of IL‐29/IL‐28Rα and/or janus kinase 2/signal transducer and activator of transcription 3 signaling using synthetic, small molecule inhibitors may be a useful strategy to reduce vascular calcification–related diseases. Vascular calcification (VC) is characterized by the deposition of calcium phosphate complexes in the arterial wall, and categorized by the intimal and medial calcification, depending on the sites of mineral deposition within the affected vessels. 1 Although it is regarded as a part of the normal aging process, VC has been implicated in the vascular pathogenesis associated with diabetes, 2 atherosclerosis, 3 and chronic kidney disease (CKD). 4 , 5 VC is considered as a hallmark of atherosclerosis and a key prognostic indicator of CKD that highly correlates with increased cardiovascular morbidity and mortality. 6 Although originally thought to be a passive, inevitable, and unregulated pathology process, VC is now appreciated to be an active and cell‐mediated process, 7 principally driven by vascular smooth muscle cells (VSMCs) 8 and tightly regulated by an array of inducers and inhibitors. 9 , 10 There is accumulating evidence suggesting that VSMC calcification plays a central role in the development and progression of VC. Importantly, phenotype sw -Abstract Truncated-

The miR-29b/Matrix Metalloproteinase 2 Axis Regulates Transdifferentiation and Calcification of Vascular Smooth Muscle Cells in a Calcified Environment

MicroRNA-29a Promotes Smooth Muscle Cell Differentiation from Stem Cells by Targeting YY1

Mechanisms of miR-29a-5p involvement in osteogenic phenotype transformation and cellular regulation of vascular smooth muscle and thus influencing calcification in VSMCs in chronic kidney disease

MicroRNA-32 Promotes Calcification in Vascular Smooth Muscle Cells: Implications As a Novel Marker for Coronary Artery Calcification.

Hypoxia-Induced MicroRNA-429 Promotes Differentiation of MC3T3-E1 Osteoblastic Cells by Mediating ZFPM2 Expression

MicroRNA-125a-mediated Regulation of the Mevalonate Signaling Pathway Contributes to High Glucose-Induced Proliferation and Migration of Vascular Smooth Muscle Cells

Upregulation of a Disintegrin and Metalloproteinase with Thrombospondin Motifs-7 by Mir-29 Repression Mediates Vascular Smooth Muscle Calcification.

MMP2 promotes osteoblast differentiation and calcification of muscle-derived mesenchymal stem cells by interaction with miR-29b-3p

MicroRNAs Are Critical in Regulating Smooth Muscle Cell Mineralization and Apoptosis During Vascular Calcification

Mir-195-5p targets Smad7 regulation of the Wnt/β-catenin pathway to promote osteogenic differentiation of vascular smooth muscle cells

MicroRNAs 29b, 133b, and 211 Regulate Vascular Smooth Muscle Calcification Mediated by High Phosphorus

Mir-33A-5p Suppresses Ox-Ldl-stimulated Calcification of Vascular Smooth Muscle Cells by Targeting METTL3

MicroRNA-34c Inhibits Osteogenic Differentiation and Valvular Interstitial Cell Calcification via STC1-Mediated JNK Pathway in Calcific Aortic Valve Disease

Overexpression of miR-204-5p Alleviates Osteogenic Differentiation and Calcification of Human Aortic Vascular Smooth Muscle Cells by Targeting Calcium/Calmodulin-dependent Protein Kinase 1

Identification of miR136, miR155, and miR183 in vascular calcification in human peripheral arteries

MiR-138-5p targets RUNX2 to inhibit osteogenic differentiation of aortic valve interstitial cells via Wnt/β-catenin signaling pathway

Vascular smooth muscle cell differentiation to an osteogenic phenotype involves matrix metalloproteinase-2 modulation by homocysteine

Mir-135A Suppresses Calcification in Senescent VSMCs by Regulating KLF4/STAT3 Pathway

Downregulation of Mir-223 and Mir-19A Induces Differentiation and Promotes Recruitment of Osteoclast Cells in Giant-Cell Tumor of the Bone Via the Runx2/TWIST-RANK/RANKL Pathway

Interleukin‐29 Accelerates Vascular Calcification via JAK2/STAT3/BMP2 Signaling

Indoxyl Sulfate Accelerates Vascular Smooth Muscle Cell Calcification Via Microrna-29B Dependent Regulation of Wnt/β-catenin Signaling.